Distinguishing ADCs Against TKIs When Targeting HER2-Mutant NSCLC – International Lung Cancer Summit

International Lung Cancer Summit shared a post on X:

“How should we distinguish ADCs versus TKIs when targeting HER2-mutant NSCLC?

At ILCS 2025, Stephanie Saw explained that while TKIs bind the intracellular domain to block phosphorylation, ADCs target the extracellular domain to trigger endocytosis and direct “cancer kill”.
With ~90% of mutations occurring in exon 20, understanding these distinct pathways might be critical for sequencing approaches with these compounds.”

Watch here

Other articles featuring International Lung Cancer Summit on OncoDaily.